Wyeth Articles
Pfizer agrees $55 million settlement for off-label promotion of Protonix by Wyeth; strikes deal over Zyvox and Lyrica
13 December 2012
Pfizer to face class action over alleged securities fraud by Wyeth
19 September 2012
Pfizer in $60 million settlement over bribery charges
8 August 2012
US Supreme Court decides for vaccine makers in Pfizer/Wyeth case
24 February 2011
Wyeth withdraws European MA application for Brilence; AstraZeneca to provide more info to US FDA on Axanum
1 June 2010
Pfizer gets US FDA approval for Prevnar 13, a Wyeth drug with blockbuster sales outlook
25 February 2010
Targeted cancer drug market set to reach $51 billion by 2015, led by Pfizer; barriers to use of oral cancer drugs identified
19 February 2010
Vernalis to re-acquire EU frovatriptan royalties; Isogenica gains rights to commercialize drugs with MRSA potential
15 February 2010
Daiichi Sankyo gains US FDA approval of Benicar to treat high BP in children and adolescent; names new VP medical affairs
12 February 2010
Burst of M&A activity in pharma during 2009 led by mega-deals from Pfizer/Wyeth and Merck & Co/S-P
4 February 2010
Pharmaceutical M&A deals in 2009
4 February 2010
The “new” Pfizer sees 4th qtr s2009 sales and profit rocket, but 2010 guidance disappoints
4 February 2010
Prioritized pipeline at “new” Pfizer marks important milestone for the company’s R&D organization
28 January 2010
Japanese Pharma market seeing more foreign entrants
21 January 2010
Pfizer’s Wyeth awarded UK contract to supply Prevenar 13; but drops European OTC ibuprofen/diphenhydramine development
20 January 2010
Pfizer fights back on HRT and cancer links highlighted by NYT
14 December 2009
Pfizer extends R&D operations in China
26 November 2009
Pfizer to be biggest beneficiary of China pharma market, say Goldman Sachs analysts; firm also set for Japanese generics market
24 November 2009
Big Pharma seeks to insulate itself from impact of ‘patent cliff’
24 November 2009
US FDA advisory panel backs Pfizer’s Prevnar 13
20 November 2009
Pfizer to close six global R&D sites as part of post-Wyeth acquisition cost-cutting
10 November 2009
Generic erosion of atypical antipsychotics will cause the bipolar disorder drug market to decline by over $1 billion through 2018
6 November 2009
Merck & Co - now world’s No 2 drugmaker - upbeat about new operation post Schering-Plough merger; but what about J&J?
5 November 2009
Pfizer 2009 3rd-qtr earnings beats forecasts, but sales weaken
21 October 2009
US Court imposes record fine and forfeiture of $1.3 billion for Pfizer unit’s fraudulent marketing of Bextra
19 October 2009
Novartis to pay up to $485 million for Paratek’s IV antibiotic
12 October 2009
UCB’s Cimzia approved for RA in Europe
7 October 2009
$4 million milestone for Ablynx in Nanobody deal with Wyeth
1 October 2009
“No Frills Drugs” push Pharma to look for a cure
30 September 2009
BIO-Europe 2009: an opportunity to hunt for deals
25 September 2009
Servier’s Valdoxan superior to Prozac for severe depression in adults
19 September 2009
Changes predicted in renal cell carcinoma market leaders
15 September 2009
Elan cures breach of Tysabri deal and amends terms of transaction
15 September 2009
Indian patent law changes will benefit Pharma multinationals
19 August 2009
Patent protection for key blockbuster depression drugs will drive growth in Europe and Japan, but not USA, says DR report
18 August 2009
US FDA says cancer warnings required for TNF blockers
5 August 2009
Wyeth donates $100K to ASCO Cancer Foundation
1 June 2009
Wyeth presents strong combo drug data at ASCO
29 May 2009
Pfizer to raise $10.6B to finance Wyeth buy
28 May 2009
Retail drug sales in year to March 2009
22 May 2009
Stock Commentary - New York week to May 18, 2009
21 May 2009
Wyeth accused of overcharging Medicaid
19 May 2009
Wyeth/Altana lose Protonix IP appeal
15 May 2009
Ligand narrows loss on rocketing revenue
8 May 2009
EVM meets EC and EMEA over swine flu
30 April 2009
Wyeth's first-quarter 2009 profit flat year-on-year as it prepares for Pfizer mega-merger
29 April 2009
Wyeth's Conbriza approved in Europe
28 April 2009
"Perverse" NICE again says "No" to new drugs
28 April 2009
URCH study foresees more pharma mega-mergers
27 April 2009
Pfizer well-positioned for Wyeth merger
24 April 2009
Retail drug sales in year to February 2009
24 April 2009
Sen Grassley probes mental health group
16 April 2009
AZ eyeing up small European firms
15 April 2009
Wyeth provides limited update
14 April 2009
Pfizer announces Wyeth execs it plans to retain
8 April 2009
FTC calls for more info on Pfizer/Wyeth deal
8 April 2009
Hospira debuts generic Tazocin in UK
7 April 2009
Elan/Wyeth pull high dose of AD drug
3 April 2009
Retail drug sales in year to January 2009
3 April 2009
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
